Opus Genetics to Unveil Early OPGx-BEST1 Data in Key Investor and Medical Presentations
Event summary
- Opus Genetics will present topline data from Cohort 1 of its Phase 1/2 study of OPGx-BEST1 on September 9, 2026, during an investor webcast.
- Full clinical dataset and additional analyses will be presented at multiple ophthalmology conferences, including Euretina 2026 and Retina in Rio.
- OPGx-BEST1 is a gene therapy designed to treat BEST1-related inherited retinal diseases using an AAV vector.
- The BIRD-1 study is an adaptive, open-label Phase 1/2 clinical trial evaluating the safety and efficacy of OPGx-BEST1.
The big picture
Opus Genetics is positioning itself as a key player in the gene therapy space for inherited retinal diseases. The upcoming presentations of OPGx-BEST1 data come at a critical juncture, as the company seeks to validate its technology and attract potential partners or investors. The broader industry is watching closely, as successful outcomes could set a precedent for other gene therapies in development.
What we're watching
- Clinical Efficacy
- How the topline data from Cohort 1 will impact the perceived efficacy and potential market positioning of OPGx-BEST1.
- Regulatory Pathway
- Whether the upcoming data presentations will accelerate regulatory discussions or approval timelines for OPGx-BEST1.
- Competitive Landscape
- The pace at which Opus Genetics can differentiate OPGx-BEST1 from other gene therapies targeting inherited retinal diseases.
Related topics